FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2407113966> ?p ?o ?g. }

• W2407113966 endingPage "e0156369" @default.
• W2407113966 startingPage "e0156369" @default.
• W2407113966 abstract "Background Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. One resistance mechanism for cediranib is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with cediranib and the oral EGFR inhibitor gefitinib improved outcome in recurrent glioblastoma. Methods and Findings This was a multi-center randomized, two-armed, double-blinded phase II study comparing cediranib plus gefitinib versus cediranib plus placebo in subjects with first relapse/first progression of glioblastoma following surgery and chemoradiotherapy. The primary outcome measure was progression free survival (PFS). Secondary outcome measures included overall survival (OS) and radiologic response rate. Recruitment was terminated early following suspension of the cediranib program. 38 subjects (112 planned) were enrolled with 19 subjects in each treatment arm. Median PFS with cediranib plus gefitinib was 3.6 months compared to 2.8 months for cediranib plus placebo (HR; 0.72, 90% CI; 0.41 to 1.26). Median OS was 7.2 months with cediranib plus gefitinib and 5.5 months with cediranib plus placebo (HR; 0.68, 90% CI; 0.39 to 1.19). Eight subjects (42%) had a partial response in the cediranib plus gefitinib arm versus five patients (26%) in the cediranib plus placebo arm. Conclusions Cediranib and gefitinib in combination is tolerated in patients with glioblastoma. Incomplete recruitment led to the study being underpowered. However, a trend towards improved survival and response rates with the addition of gefitinib to cediranib was observed. Further studies of the combination incorporating EGFR and VEGF inhibition are warranted. Trial Registration ClinicalTrials.gov NCT01310855" @default.
• W2407113966 created "2016-06-24" @default.
• W2407113966 creator A5007865366 @default.
• W2407113966 creator A5015933098 @default.
• W2407113966 creator A5018526947 @default.
• W2407113966 creator A5023774687 @default.
• W2407113966 creator A5026323326 @default.
• W2407113966 creator A5033410310 @default.
• W2407113966 creator A5033611186 @default.
• W2407113966 creator A5040614492 @default.
• W2407113966 creator A5044767725 @default.
• W2407113966 creator A5050246084 @default.
• W2407113966 creator A5050819642 @default.
• W2407113966 creator A5058245772 @default.
• W2407113966 creator A5061818587 @default.
• W2407113966 creator A5064184281 @default.
• W2407113966 creator A5065569878 @default.
• W2407113966 date "2016-05-27" @default.
• W2407113966 modified "2023-10-17" @default.
• W2407113966 title "Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma" @default.
• W2407113966 cites W1556788203 @default.
• W2407113966 cites W1970174108 @default.
• W2407113966 cites W1973071934 @default.
• W2407113966 cites W1976578289 @default.
• W2407113966 cites W1978041336 @default.
• W2407113966 cites W1979867859 @default.
• W2407113966 cites W1982162307 @default.
• W2407113966 cites W1982174962 @default.
• W2407113966 cites W2002884377 @default.
• W2407113966 cites W2013631005 @default.
• W2407113966 cites W2023977554 @default.
• W2407113966 cites W2024233733 @default.
• W2407113966 cites W2043702724 @default.
• W2407113966 cites W2049229287 @default.
• W2407113966 cites W2050247332 @default.
• W2407113966 cites W2051120695 @default.
• W2407113966 cites W2059624809 @default.
• W2407113966 cites W2059890247 @default.
• W2407113966 cites W2060877959 @default.
• W2407113966 cites W2082806449 @default.
• W2407113966 cites W2096287682 @default.
• W2407113966 cites W2097373408 @default.
• W2407113966 cites W2100673960 @default.
• W2407113966 cites W2108042184 @default.
• W2407113966 cites W2117941094 @default.
• W2407113966 cites W2121889629 @default.
• W2407113966 cites W2125885051 @default.
• W2407113966 cites W2126655764 @default.
• W2407113966 cites W2127745545 @default.
• W2407113966 cites W2129851137 @default.
• W2407113966 cites W2132697290 @default.
• W2407113966 cites W2140375000 @default.
• W2407113966 cites W2141448895 @default.
• W2407113966 cites W2144242568 @default.
• W2407113966 cites W2145854263 @default.
• W2407113966 cites W2145978086 @default.
• W2407113966 cites W2150335765 @default.
• W2407113966 cites W2158681922 @default.
• W2407113966 cites W2160959204 @default.
• W2407113966 cites W2162643152 @default.
• W2407113966 cites W2169590480 @default.
• W2407113966 cites W2395830793 @default.
• W2407113966 cites W4245392732 @default.
• W2407113966 doi "https://doi.org/10.1371/journal.pone.0156369" @default.
• W2407113966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4883746" @default.
• W2407113966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27232884" @default.
• W2407113966 hasPublicationYear "2016" @default.
• W2407113966 type Work @default.
• W2407113966 sameAs 2407113966 @default.
• W2407113966 citedByCount "37" @default.
• W2407113966 countsByYear W24071139662016 @default.
• W2407113966 countsByYear W24071139662018 @default.
• W2407113966 countsByYear W24071139662020 @default.
• W2407113966 countsByYear W24071139662021 @default.
• W2407113966 countsByYear W24071139662022 @default.
• W2407113966 countsByYear W24071139662023 @default.
• W2407113966 crossrefType "journal-article" @default.
• W2407113966 hasAuthorship W2407113966A5007865366 @default.
• W2407113966 hasAuthorship W2407113966A5015933098 @default.
• W2407113966 hasAuthorship W2407113966A5018526947 @default.
• W2407113966 hasAuthorship W2407113966A5023774687 @default.
• W2407113966 hasAuthorship W2407113966A5026323326 @default.
• W2407113966 hasAuthorship W2407113966A5033410310 @default.
• W2407113966 hasAuthorship W2407113966A5033611186 @default.
• W2407113966 hasAuthorship W2407113966A5040614492 @default.
• W2407113966 hasAuthorship W2407113966A5044767725 @default.
• W2407113966 hasAuthorship W2407113966A5050246084 @default.
• W2407113966 hasAuthorship W2407113966A5050819642 @default.
• W2407113966 hasAuthorship W2407113966A5058245772 @default.
• W2407113966 hasAuthorship W2407113966A5061818587 @default.
• W2407113966 hasAuthorship W2407113966A5064184281 @default.
• W2407113966 hasAuthorship W2407113966A5065569878 @default.
• W2407113966 hasBestOaLocation W24071139661 @default.
• W2407113966 hasConcept C121608353 @default.
• W2407113966 hasConcept C126322002 @default.
• W2407113966 hasConcept C142724271 @default.
• W2407113966 hasConcept C143998085 @default.
• W2407113966 hasConcept C204787440 @default.

• next